BridGene Biosciences Raises $28 Million in Series B+ Financing Led by Bayland Capital to Advance BGC-515 and Expand Platform.
Amount Raised
$28 Million
Round Type
Series B
San JoseBiotechnologyTherapeuticsInvestors
Description
BridGene Biosciences, a leader in small molecule drug development, announced a $28 million Series B+ funding led by Bayland Capital. The funds will be used to advance BGC-515 through clinical development and support additional oncology programs. This financing will also enhance BridGene's ability to expand its strategic collaborations and validate its IMTAC™ platform. CEO Ping Cao highlighted the significance of this funding for their lead program and pipeline development.
Quick answer
BridGene Biosciences raised $28 Million in a Series B round, dated October 16, 2025. Investors: Gtja Investment Group, Proxima Ventures, Lapam Capital, Grains Valley Venture Capital and Bayland Capital. BridGene Biosciences is based in San Jose, California, United States.
- How much did BridGene Biosciences raise?
- BridGene Biosciences raised $28 Million in a Series B round on October 16, 2025.
- Who invested in BridGene Biosciences?
- Gtja Investment Group, Proxima Ventures, Lapam Capital, Grains Valley Venture Capital and Bayland Capital are named as investors in this round.
- What does BridGene Biosciences do?
- BridGene Biosciences is a biotechnology company pioneering the discovery and development of innovative small-molecule drugs that target traditionally undruggable targets.
- Where is BridGene Biosciences based and how big is it?
- BridGene Biosciences is based in San Jose, California, United States. Fundz records about 33 employees.
- Who are the decision-makers at BridGene Biosciences?
- Fundz holds 1 contact at BridGene Biosciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as BridGene Biosciences that raised within 45 days of this round, from Fundz verified event records.
- Azora Therapeutics, Inc. (DE) raised $4.3M on November 28, 2025.
- SymPhysis Medical raised $1.3M (Grant) on November 26, 2025.
- Azitra raised $5M (Post-IPO Equity) on November 25, 2025.
- Verrica raised $50M on November 25, 2025.
- MindImmune Therapeutics raised $10M (Series A) on November 24, 2025.
- FibroBiologics raised $1.5M on November 24, 2025.
Who to call at BridGene Biosciences, and when
A new round usually means BridGene Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day BridGene Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BridGene Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BridGene Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BridGene Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansBridGene Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.